Heterodimer molecule based on ch3 domain, and preparation method and use thereof
AssigneesJiangsu Alphamab Biopharmaceuticals Co., Ltd., Suzhou Alphamab Co., Ltd.
InventorTing XU
Life of this patent
Estimating the term…
Abstract
The disclosure is directed to a heterodimer molecule, comprising a first polypeptide chain and a second polypeptide chain, and the first polypeptide chain comprises a first CH3 domain of an antibody heavy chain constant region, the second polypeptide chain comprises a second CH3 domain of an antibody heavy chain constant region. Comparing to a corresponding wild-type CH3 domain of a human antibody heavy chain constant region, the first CH3 domain and the second CH3 domain comprise amino acid mutations at specific positions, for example T366+K409+K392 and T366+L368+Y407+D399+F405, respectively.
Claims21
-29. (canceled)
A heterodimer molecule, comprising a first polypeptide chain and a second polypeptide chain, wherein said first polypeptide chain comprises a first CH3 domain of an antibody heavy chain constant region, said second polypeptide chain comprises a second CH3 domain of an antibody heavy chain constant region, and comparing to a corresponding wild-type CH3 domain of a human antibody heavy chain constant region, said first CH3 domain and said second CH3 domain comprise an amino acid mutation as following:
- an amino acid mutation at T366 and F405 of said first CH3 domain, and an amino acid mutation at T366, L368, Y407 and K409 of said second CH3 domain, and optionally said first CH3 domain and/or said second CH3 domain further comprise an amino acid mutation at 1-2 residues selected from the group consisting of K392, D399, Y349, S354 and E357;
- wherein said amino acid is numbered according to the EU index of the KABAT numbering of the antibody Fc region.
Dependencies are inferred from the claim text.